Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

VHCP Management Produced Impressive Returns From Its Pharma Stock Picks In The Turbulent Third Quarter

Page 1 of 3

With losses in the high single-digits and volatility hitting the roof, the third quarter of 2015 turned out to be a troublesome period for the equity markets. While a lot of asset management firms suffered serious setbacks during this period, there were a few who not only lived through it with minimum damage, but were also able to generate superior returns. Andres Hove and Bong Koh’s healthcare-focused hedge fund VHCP Management was one such firm. We calculate the stock picking performance of a hedge fund based on the weighted average returns of its picks in companies with market capitalizations of over $1 billion. As we don’t take into account short positions or positions in bonds or options, it is possible that the returns estimated by us differ greatly from the actual performance of the fund. Based on this metric, VHCP Management’s picks returned 17.38% for the third quarter and 58.5% for the first nine months of 2015. To put that in perspective, out of 649 funds in our database for which we calculated third quarter returns, the next-best performance stood at just 2.88% for the third quarter and just seven funds generated positive returns from their stock picks during that period, using our method of calculations. Given that, in this article we are going to take a closer look at VHCP Management’s top five equity holdings at the end of the second quarter and figure out which of them played a key role in the fund’s spectacular performance during the third quarter.

Biotech Biochemical Stocks BLRX 3

Venrock Healthcare Capital Partners, L.P. (VHCP) was founded as a venture capital arm of the Rockefeller family by Laurence S. Rockefeller in 1969. Although the firm mostly invested in technology companies in its early years, over the course of time it gyrated towards investing primarily in publicly-held, development-stage and late-stage private healthcare companies. VHCP Management is currently managed by partners Andres Hove and Bong Koh. While Mr. Hove served as the CEO of Bellevue Asset Management prior to joining VHCP in 2004 and holds an M.B.A. from INSEAD, Mr. Koh boasts an M.B.A. from Harvard Business School and prior to joining VHCP in 2009 was an active investor in public and private markets since 2004.  At the end of June, VHCP Management’s U.S public equity portfolio was worth nearly $354.5 million and all of it was invested in healthcare companies.

Anders Hove And Bong Koh
Anders Hove And Bong Koh
VHCP Management

We pay attention to hedge funds’ moves because our research has shown that hedge funds are extremely talented at picking stocks on the long side of their portfolios. It is true that hedge fund investors have been underperforming the market in recent years. However, this was mainly because hedge funds’ short stock picks lost a ton of money during the bull market that started in March 2009. Hedge fund investors also paid an arm and a leg for the services that they received. We have been tracking the performance of hedge funds’ 15 most popular small-cap stock picks in real time since the end of August 2012. These stocks have returned 118% since then and outperformed the S&P 500 Index by over 60 percentage points (see the details here). That’s why we believe it is important to pay attention to hedge fund sentiment; we also don’t like paying huge fees.

Let’s start with VHCP’s largest equity holding at the end of the second quarter, Anacor Pharmaceuticals Inc (NASDAQ:ANAC). As of June 30, the fund held nearly 1.18 million shares of the company, worth $91.25 million. Owing mostly to the over 50% gains that Anacor Pharmaceuticals Inc (NASDAQ:ANAC)’s shares enjoyed on July 13 after the company announced promising results from late-stage (phase III) studies done on its topical skin ointment, ‘ Crisaborole’, shares of the company ended the third quarter with gains of 52% and are currently trading with year-to-date gains of 270%. On September 9, analysts at JMP Securities initiated coverage on Anacor’s stock with a price target of $173, which represents a potential upside of 47.8% from the stock’s current trading price. Among the hedge funds we track, Julian Baker and Felix Baker‘s Baker Bros. Advisors was the largest shareholder of Anacor Pharmaceuticals Inc (NASDAQ:ANAC) at the end of the second quarter, owning over 3.62 million shares.

Follow Anacor Pharmaceuticals Inc. (NASDAQ:ANAC)
Trade (NASDAQ:ANAC) Now!

Page 1 of 3

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!